New method expected to speed understanding of short telomere diseases and cancer
Since the Nobel Prize-winning discovery of the enzyme telomerase in 1984, identifying other biological molecules that lengthen or shorten the protective caps on the ends of chromosomes has been slow going. Now, researchers at Johns Hopkins report uncovering the role of an enzyme crucial to telomere length and say the new method they used to find it should speed discovery of other proteins and processes that determine telomere length. Their results appear in the Nov. 24 issue of Cell Reports.
Telomeres glow at the end of chromosomes.
Credit: Hesed Padilla-Nash and Thomas Ried of the NIH
"We've known for a long time that telomerase doesn't tell the whole story of why chromosomes' telomeres are a given length, but with the tools we had, it was difficult to figure out which proteins were responsible for getting telomerase to do its work," says Carol Greider, Ph.D., the Daniel Nathans Professor and Director of Molecular Biology and Genetics in the Johns Hopkins Institute for Basic Biomedical Sciences. Greider won the 2009 Nobel Prize in Physiology or Medicine for the discovery of telomerase.
Figuring out exactly what's needed to lengthen telomeres has broad health implications, Greider notes, because shortened telomeres have been implicated in aging and in diseases as diverse as lung and bone marrow disorders, while overly long telomeres are linked to cancer. Because telomeres naturally shorten each time DNA is copied in preparation for cell division, cells need a well-tuned process to keep adding the right number of building blocks back onto telomeres over an organism's lifetime.
But until now researchers have been saddled with a limiting and time-consuming test for whether a given protein is involved in maintaining telomere length, a test that first requires blocking a suspected protein's action in lab-grown cells, then getting the cells to grow and divide for about three months so that detectable differences in telomere length can emerge. In addition to being time consuming, the test could not be used at all for proteins whose loss would kill the cells before the three-month mark.
To find a better tool, graduate student Stella Suyong Lee, working in Greider's laboratory, started with a concept used for measuring telomere length in yeast. The idea was to artificially cut mammalian cells' telomeres, then detect elongation by telomerase -- a test that would take less than a day, and could be performed even if the blocked proteins were needed for cells to divide. But making the transition from yeast to mammals involved a host of unforeseen technical difficulties, and the project took nearly five years. Greider credits Lee's persistence for its eventual success.
For their trial run of the new test, dubbed addition of de novo initiated telomeres (ADDIT), Greider's group examined an enzyme called ATM kinase. "ATM kinase was known to be involved in DNA repair, but there were conflicting reports about whether it had a role in telomere lengthening," says Greider. Her team blocked the enzyme in lab-grown mouse cells, and used ADDIT to find that it was indeed needed to lengthen telomeres. They verified the result using the old, three-month-long telomere test, and got the same result.
The team also found that in normal mouse cells, a drug that blocks an enzyme called PARP1 would activate ATM kinase and spur telomere lengthening. This finding offers a proof of principle for drug-based telomere elongation to treat short-telomere diseases, such as bone marrow failure, Greider says -- but she cautions that PARP1 inhibitor drug itself doesn't have the same telomere-elongating effect in human cells as it does in mouse cells.
Greider's group plans to use ADDIT to find out more about the telomere-lengthening biochemical pathway that ATM kinase is a part of, as well as other pathways that help determine telomere length. "The potential applications are very exciting," Lee says. "Ultimately ADDIT can help us understand how cells strike a balance between aging and the uncontrolled cell growth of cancer, which is very intriguing."
Other authors on the paper are Craig Bohrson, Alexandra Mims Pike and Sarah Jo Wheelan, all of Johns Hopkins University School of Medicine.
This study was funded by the National Institute on Aging (grant number R37AG009383), the Turock Fellowship, and a Commonwealth Foundation Grant.
Shawna Williams | EurekAlert!
Closing the carbon loop
08.12.2016 | University of Pittsburgh
Newly discovered bacteria-binding protein in the intestine
08.12.2016 | University of Gothenburg
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy
08.12.2016 | Materials Sciences